Digitala Vetenskapliga Arkivet

Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Synthesis and preclinical evaluation of gastrin releasing peptide receptor antagonist [18F]MeTz-PEG2-RM26 for positron emission tomography
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Medicinal Chemistry, Theranostics.ORCID iD: 0000-0002-0617-3936
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Medicinal Chemistry, Preparative Medicinal Chemistry.ORCID iD: 0000-0002-9153-2832
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Medicinal Chemistry, Theranostics. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Medicinal Chemistry, Translational PET Imaging.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Medicinal Chemistry.ORCID iD: 0000-0002-4664-3445
Show others and affiliations
2025 (English)In: EJNMMI Radiopharmacy and Chemistry, E-ISSN 2365-421X, Vol. 10, no 1, article id 14Article in journal (Refereed) Published
Abstract [en]

Background: The gastrin-releasing peptide receptor (GRPR) is overexpressed in the majority of primary prostate cancer lesions, with persistent expression in lymph nodes and bone metastases, making it a legitimate molecular target for diagnostic imaging and staging. This study presents the synthesis and preclinical evaluation of [18F]MeTz-PEG2-RM26, a GRPR antagonist which utilises the Inverse Electron Demand Diels-Alder (IEDDA) reaction for 18F-labelling. This click-chemistry approach allows for site-specific incorporation of fluorine-18 under mild conditions, preserving the peptide's structural integrity and biological activity. Receptor specificity and affinity of [18F]MeTz-PEG2-RM26 were evaluated in vitro using GRPR-expressing PC-3 cells. Furthermore, the biodistribution profile of [18F]MeTz-PEG2-RM26 was assessed in NMRI mice and its tumour-targeting capability was investigated in mice bearing PC-3 xenografts.

Results: The labelling of TCO-PEG2-RM26 precursor involved three steps: (1) synthesis of an 18F-labelled activated ester on a quaternary methyl ammonium (QMA) cartridge, (2) conjugation of the labelled ester to a tetrazine amine, and (3) attachment to TCO-PEG2-RM26 via an IEDDA click reaction. This production method of [18F]MeTz-PEG2-RM26 afforded a high apparent molar activity of 3.5-4.3 GBq/mu mol and radiochemical purity exceeding 98%, with 43-70 MBq activity incorporation, while the entire synthesis was completed within 75 min. Both in vitro and in vivo studies confirmed the specific binding of [18F]MeTz-PEG2-RM26 to GRPR, with a significant reduction in activity uptake observed upon receptor saturation. The radioligand exhibited rapid blood clearance and minimal bone uptake, confirming the stability of the fluorine-carbon bond. However, high hepatic uptake (12-13% IA/g at 1 h post-injection) indicated predominant hepatobiliary excretion. Receptor-mediated uptake was observed in the tumours and pancreatic tissue, although the overall activity uptake in tumours was low, likely due to the rapid hepatobiliary clearance of [18F]MeTz-PEG2-RM26.

Conclusions:  These findings demonstrate the effectiveness of the IEDDA click reaction for fluorine-18 labelling of GRPR-targeting PET tracers. Future studies should focus on increasing the hydrophilicity of the imaging probe to improve the targeting properties and biodistribution profile of the radioligand.

Place, publisher, year, edition, pages
Springer Nature, 2025. Vol. 10, no 1, article id 14
Keywords [en]
Fluorine-18, TCO, Tetrazine, IEDDA click chemistry, GRPR, Bombesin, PET, Prostate cancer
National Category
Radiology and Medical Imaging Medicinal Chemistry Cancer and Oncology Pharmaceutical Sciences
Identifiers
URN: urn:nbn:se:uu:diva-553823DOI: 10.1186/s41181-025-00336-9ISI: 001453646400001PubMedID: 40138074Scopus ID: 2-s2.0-105000840760OAI: oai:DiVA.org:uu-553823DiVA, id: diva2:1950403
Available from: 2025-04-07 Created: 2025-04-07 Last updated: 2025-04-07Bibliographically approved

Open Access in DiVA

fulltext(1534 kB)27 downloads
File information
File name FULLTEXT01.pdfFile size 1534 kBChecksum SHA-512
19b46cf4bbc5a198cb5b9ecbc0966bd0555d92a63927c9e15b8cd544f4ba97c8ea3ece43daf625bf455fe00ed20367c35ad0dfa03c7c47a71c3c2bdee324fc49
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMedScopus

Search in DiVA

By author/editor
Kanellopoulos, PanagiotisLundmark, FannyAbouzayed, AymanBalestri, Lorenzo Jacopo IlicOlaniran, EstherObeid, KarimOdell, Luke R.Tolmachev, Vladimir M.Rosenström, UlrikaEriksson, JonasOrlova, Anna
By organisation
TheranosticsPreparative Medicinal ChemistryTranslational PET ImagingDepartment of Medicinal ChemistryCancer precision medicineScience for Life Laboratory, SciLifeLab
In the same journal
EJNMMI Radiopharmacy and Chemistry
Radiology and Medical ImagingMedicinal ChemistryCancer and OncologyPharmaceutical Sciences

Search outside of DiVA

GoogleGoogle Scholar
Total: 27 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 231 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf